Tag Archives: vrx

Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

Prices for prescription skin drugs to treat everything from acne to skin cancer are skyrocketing, a report out Wednesday found, adding to the public debate about how much drugmakers ought to charge. A study published in JAMA Dermatology said that a survey of 19 brand-name prescription drugs, including those from Valeant Pharmaceuticals (VRX), GlaxoSmithKline (GSK) and Novartis (NVS), found their prices jumped 401% on average between 2009 and 2015.

KaloBios, Valeant Lead Week’s 5 Top Drug Stock Gainers

Medical spending tends to rise steadily, but drug stocks can see huge swings as clinical trials, FDA reviews and other news buoy or torpedo the outlook. This week’s 5 big drug winners* rallied for diverse reasons. KaloBios Pharmaceuticals (KBIO) skyrocketed as new buyers stepped in before liquidation. Valeant Pharmaceuticals (VRX) rebounded after a huge sell-off. Sarepta Therapeutics (SRPT) benefited from a rival’s bad news. Voyager Therapeutics

Gilead, Regeneron Stocks Weather Drug Pricing Furor

Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry’s drug-pricing practices and fears of greater regulation. But two biotechs with top fundamentals — Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN), the focus of the Screen of the Day — have maintained strong ratings and held up in